BiotechTube

Savolitinib + MEDI4736 + Tremelimumab

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Renal Clear Cell Carcinoma

Conditions

Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma

Trial Timeline

May 3, 2016 → Jul 17, 2024

NCT ID
NCT02819596

About Savolitinib + MEDI4736 + Tremelimumab

Savolitinib + MEDI4736 + Tremelimumab is a phase 2 stage product being developed by AstraZeneca for Renal Clear Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02819596. Target conditions include Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma.

What happened to similar drugs?

20 of 20 similar drugs in Renal Clear Cell Carcinoma were approved

Approved (20) Terminated (0) Active (0)
✅tacrolimus + CellCept + steroids (methylprednisone or prednisone)Astellas PharmaApproved
✅Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + PrednisoloneAstellas PharmaApproved
✅Tacrolimus, Prograf®Astellas PharmaApproved
✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved
✅Tacrolimus - Prograf® twice daily formulation + Tacrolimus - Advagraf® once daily formulationAstellas PharmaApproved
✅Tacrolimus + CyclosporineAstellas PharmaApproved
✅Tacrolimus sustained-release capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02819596Phase 2Completed

Competing Products

20 competing products in Renal Clear Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
23
LY3473329Eli LillyPhase 1
29
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
35
LY3819469Eli LillyPhase 1
29
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
32
DS-6000a + DS-6000aDaiichi SankyoPhase 1
33
DS-1093aDaiichi SankyoPhase 1
29
CS-3150Daiichi SankyoPhase 3
40
AGS-16C3FAstellas PharmaPhase 1
29
AGS-16M8FAstellas PharmaPhase 1
29
CP-461Astellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 3
40
YM178Astellas PharmaPhase 1
29
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
29
bixalomerAstellas PharmaPre-clinical
26